Speaker
Description
Tumor Mutational Burden (TMB) is a key biomarker for immunotherapy response but is costly and time-consuming to assess via sequencing. This study explores ultra-high frequency dielectrophoresis (UHF-DEP) as a rapid, label-free alternative by analyzing the electromagnetic signature (EMS) of cancer cells.
Using a lab-on-a-chip biosensor, UHF-DEP crossover frequencies (CFs) were measured in eight solid tumor cell lines. EMS values correlated with TMB, distinguishing between high (≥10 Mut/Mb) and low TMB cell lines.
These findings suggest UHF-DEP could provide a rapid TMB estimation method, improving patient stratification for immunotherapy. Further studies are needed to validate EMS as a clinical biomarker and assess its complementarity with sequencing.
